Cathie Wood’s ARK sells Teradyne stock, buys Tesla

ARK sold 25,240 shares of Teradyne (TER) for $7.814M and purchased 39,691 shares of Tesla (TSLA) for $14.312M on April 6, 2026. Other notable moves: sales of 29,773 BWX Technologies for $6.401M, 8,484 Cameco (CCJ) for $0.955M, and 92,758 Strata Critical Medical (SRTA) for $0.385M, while adding 4,394 Kodiak AI (KDK) for $0.033M. Trades reflect continued reduction in Teradyne and Strata positions and increased conviction in Tesla and incremental accumulation of Kodiak, indicating portfolio reweighting by ARK rather than market-wide news.

Analysis

Recent flows indicate a rotation away from capital goods cyclicals into EV/AI narratives — a dynamic that pressures ATE/test-equipment vendors through two channels: negative mark-to-market from systematic funds and an elongation of the order book as OEMs postpone spending. That second-order inventory effect tends to hit small and mid-cap test-equipment suppliers hardest (long lead times, concentrated customers), creating a multi-month earnings surprise risk even if end-market demand recovers later in the cycle.

Large-scale buying interest in EV/AI platform names is functioning as both a confidence signal and a volatility suppressor: concentrated accumulation by thematic funds reduces float available to retail and dealers, compressing realized vol and buoying spot multiple – but it also seeds convex downside if sentiment reverses. This creates a favorable environment for directional option structures that sell premium against a core long exposure to capture decay while retaining upside to fundamental re-rating over 6–12 months.

Small-cap AI/AV and specialty healthcare moves highlight liquidity-driven repositioning rather than pure conviction in fundamentals; these names can gap violently on flows. Geopolitical tail risks remain live and asymmetric — an escalation would reprice nuclear and defense exposure in days, so trades should incorporate event-driven hedges and tight sizing rather than pure buy-and-hold allocations.

Key Decisions for Investors

• Long TSLA via a 9–12 month call spread (buy long-dated calls, sell higher strike to finance ~50–70% of premium). Size 2–3% NAV. Rationale: capture multi-product TAM optionality while limiting theta bleed; target 2–3x gross return if TSLA re-rates or posts positive autonomy/energy headlines. Stop: narrow if 20% adverse move in underlying within 6 weeks.
• Short TER (Teradyne) outright or buy 3–6 month put spreads sized 0.5–1% NAV. Rationale: exploit order-book elongation and flow-driven liquidation pressure in ATE names. Risk: semiconductor capex recovery; hard stop at 15–20% adverse price move or unwind on accelerating book-to-bill metrics.
• Small, exploratory long in KDK (Kodiak AI) — direct shares or 12–24 month LEAPS sized 0.25–0.5% NAV. Rationale: optional exposure to AV/AI stack with asymmetric upside if development milestones are met. Risk control: 30% stop-loss and re-evaluate on quarterly tech milestones.
• Pair trade for medium-term (3–12 months): long CCJ (uranium exposure) financed by short BWXT (nuclear services) sized net 1–2% NAV. Rationale: capture a potential near-term commodity rerating while neutralizing some sector beta; protect against binary geopolitical spikes by buying a small tail put on BWXT. Risk: both can rally in an escalation — monitor geopolitics and maintain event hedges.